260 related articles for article (PubMed ID: 15867257)
21. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
22. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma.
Hara I; Taguchi I; Miyake H; Hara S; Gotoh A; Kamidono S
Int J Oncol; 2001 Nov; 19(5):959-62. PubMed ID: 11604994
[TBL] [Abstract][Full Text] [Related]
23. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells.
Shimizu M; Suzui M; Deguchi A; Lim JT; Xiao D; Hayes JH; Papadopoulos KP; Weinstein IB
Clin Cancer Res; 2004 Oct; 10(19):6710-21. PubMed ID: 15475462
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Camphausen K; Scott T; Sproull M; Tofilon PJ
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
[TBL] [Abstract][Full Text] [Related]
27. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
[TBL] [Abstract][Full Text] [Related]
28. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
29. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
30. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.
Hoffman AD; Engelstein D; Bogenrieder T; Papandreou CN; Steckelman E; Dave A; Motzer RJ; Dmitrovsky E; Albino AP; Nanus DM
Clin Cancer Res; 1996 Jun; 2(6):1077-82. PubMed ID: 9816270
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids.
Peng X; Yun D; Christov K
Int J Oncol; 2004 Oct; 25(4):961-71. PubMed ID: 15375546
[TBL] [Abstract][Full Text] [Related]
32. Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth.
Li Q; O'Malley ME; Bartlett DL; Guo ZS
Mol Cancer; 2011 May; 10():63. PubMed ID: 21609483
[TBL] [Abstract][Full Text] [Related]
33. Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells.
Wallden B; Emond M; Swift ME; Disis ML; Swisshelm K
BMC Cancer; 2005 Oct; 5():140. PubMed ID: 16255778
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.
Blagitko-Dorfs N; Jiang Y; Duque-Afonso J; Hiller J; Yalcin A; Greve G; Abdelkarim M; Hackanson B; Lübbert M
PLoS One; 2013; 8(10):e75258. PubMed ID: 24116031
[TBL] [Abstract][Full Text] [Related]
35. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
36. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.
Whang YM; Choi EJ; Seo JH; Kim JS; Yoo YD; Kim YH
Cancer Chemother Pharmacol; 2005 Nov; 56(5):543-55. PubMed ID: 15959780
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation associated with polycomb repression in retinoic acid receptor β silencing.
Moison C; Senamaud-Beaufort C; Fourrière L; Champion C; Ceccaldi A; Lacomme S; Daunay A; Tost J; Arimondo PB; Guieysse-Peugeot AL
FASEB J; 2013 Apr; 27(4):1468-78. PubMed ID: 23299856
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway.
Lefebvre B; Brand C; Flajollet S; Lefebvre P
Mol Endocrinol; 2006 Sep; 20(9):2109-21. PubMed ID: 16613989
[TBL] [Abstract][Full Text] [Related]
39. Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma.
Taguchi I; Hara I; Gohji K; Arakawa S; Kamidono S
Int J Oncol; 1998 Jul; 13(1):145-9. PubMed ID: 9625816
[TBL] [Abstract][Full Text] [Related]
40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
